NEW

4 Groups Provide Guidance on Maintaining Essential Operations

ACS, AHA, ASA and AORN develop roadmap for safely managing surgical patients during a time of resurgence

Exactech Appoints New Chief Financial Officer

Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, has announced Kerem Bolukbasi as its new chief financial officer (CFO). Bolukbasi joins Exactech from TPG Capital where he...

Philips launches Rapid Equipment Deployment Kit to COVID-19 response

Royal Philips has introduced its Rapid Equipment Deployment Kit for ICU ramp-ups, allowing doctors, nurses, technicians and hospital staff to quickly support critical care patient monitoring capabilities during the COVID-19 pandemic. Currently successfully in use in...

Pure Processing Hires New CFO

Pure Processing LLC, developer and provider of pre-cleaning stations, technologies and accessories for health care reprocessing departments, has announced the appointment of Carrie Pasinski, an experienced finance and operations leader, as chief financial officer for...

Baxter to Broaden Portfolio of Surgical Products

Baxter International Inc. has announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction.

“Uncontrolled intraoperative bleeding can lead to a wide variety of clinical and economic complications for patients and hospitals. As a provider of advanced hemostats and sealants, Baxter is focused on continually identifying solutions to help meet surgeons’ varying needs,” said Wil Boren, president of Baxter’s Advanced Surgery business. “We are excited about the addition of RECOTHROM to help surgeons address less severe intraoperative bleeding and PREVELEAK to complement Baxter’s existing portfolio of sealants for cardiovascular and other surgical specialties.”

The transaction is expected to close in the first half of 2018, subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X